What is the latest in SMA and SBMA Research?
In MDA’s pursuit to find treatments and cures for neuromuscular diseases we awarded four grants to researchers studying SBMA and SMA in 2017. Check out their research here:
Tag: Spinal-Bulbar Muscular Atrophy (SBMA)
Five Questions with Researcher Andrew Lieberman
Andrew Lieberman of the University of Michigan Medical School was awarded an MDA research grant to test a modified antisense oligonucleotide (ASO) therapy to treat spinal-bulbar muscular atrophy.
MDA Grants Work to Find Breakthroughs Across Diseases
Since its inception, MDA has invested more than $1 billion in neuromuscular disease research to uncover new treatments and cures. In 2016 alone, MDA awarded 66 new research, development and research infrastructure grants with a total funding commitment of more than $17 million. These and other MDA grants fund research projects designed to uncover the . . .
New Research Grants Aim to Help MDA Families Live Unlimited
This summer MDA challenged our families, friends, sponsors, staff and others around the nation to share their stories about living life without limits despite the challenges of neuromuscular disease. Some shared moments tied to pursuing an education or career that was thought to be out of reach. Some talked about skydiving, hiking or running a . . .
SBMA – Diane Merry, Ph.D.
Diane Merry, associate professor at Thomas Jefferson University in Philadelphia, was awarded an MDA research grant totaling $300,000 over three years to identify therapeutic opportunities to promote normal androgen receptor function while preventing the toxic effects of polyglutamine expansion in spinal-bulbar muscular atrophy (SBMA). Working with GlaxoSmithKline, Merry will test small molecule compounds that activate . . .
Five Questions with SBMA Researcher Diane Merry
Diane Merry, associate professor at Thomas Jefferson University in Philadelphia, is working to identify therapeutic opportunities to promote normal androgen receptor function while preventing the toxic effects of polyglutamine expansion in spinal-bulbar muscular atrophy (SBMA). With GlaxoSmithKline, Merry will test small molecule compounds that activate an enzyme called SIRT1 in cell and mouse models of . . .
